Remdesivir batch withdrawn due to inferior quality: Maharashtra govt

Tope further said NCP chief Sharad Pawar has stepped in and assured to arrange 1,000 injections of Remdesivir in his personal capacity for the treatment of people.

A batch of Remdesivir for

treatment of COVID-19 patients has been withdrawn in view of "sub-standard quality" of the medicine, Maharashtra Health Minister Rajesh Tope said on Wednesday.

He told reporters that the move caused a short-term shortage of the drug in the state.

"A batch of Remdesivir medicine was found to be (of) substandard (quality) and has been withdrawn, resulting into a short term shortage in its supply," he said.

Seeking to allay concerns over shortage of Remdesivir, the minister said the government held talks with pharma companies and ensured sufficient supply of the medicine for COVID-19 patients.

"I spoke to collectors of various districts in the state and asked them to place orders of the medicine (Remdesivir) as per their respective requirement. Its supply will soon increase and patients will get their routine dosages," the minister said.

Tope further said NCP chief Sharad Pawar has stepped in and assured to arrange 1,000 injections of Remdesivir in his personal capacity for the treatment of people.

Maharashtra had 2,72,410 active cases as on September 22 while the total caseload stood at 12,42,770.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel